{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:44:47Z","timestamp":1767962687755,"version":"3.49.0"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ctrv.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T18:31:52Z","timestamp":1380652312000},"page":"220-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Time for more optimism in metastatic breast cancer?"],"prefix":"10.1016","volume":"40","author":[{"given":"El\u017cbieta","family":"Senkus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.09.015_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2013.09.015_b0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0020","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0025","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0030","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0035","author":"Metzger-Filho","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0040","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-7-134","article-title":"Use of immunohistochemical markers can refine prognosis in triple negative breast cancer","volume":"7","author":"Tischkowitz","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/annonc\/mdl334","article-title":"Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5years of tamoxifen","volume":"18","author":"Kennecke","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1755-8794-4-3","article-title":"Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures","volume":"4","author":"Fan","year":"2011","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.ctrv.2013.09.015_b0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jnci\/djq526","article-title":"Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies","volume":"103","author":"Yang","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0065","doi-asserted-by":"crossref","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","article-title":"Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies","volume":"7","author":"Blows","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0070","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ctrv.2012.06.011","article-title":"A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women","volume":"39","author":"Cardoso","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2013.09.015_b0080","series-title":"Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)","author":"Gibson","year":"2009"},{"key":"10.1016\/j.ctrv.2013.09.015_b0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11204810-000000000-00000","article-title":"Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women","volume":"71","author":"Croxtall","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2013.09.015_b0090","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-012-2192-4","article-title":"Fulvestrant 500mg versus anastrozole 1mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized \u2018FIRST\u2019 study","volume":"136","author":"Robertson","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0095","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2013.09.015_b0100","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(12)70687-1","article-title":"Fulvestrant alone or with concomitant anastrozole vs. exemestane following progression on non-steroidal aromatase inhibitor-first results of the Sofea trial (cruke\/03\/021 and cruk\/09\/007) (isrctn44195747)","volume":"48","author":"Johnston","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0105","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0115","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0135","first-page":"2261","article-title":"Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study","volume":"19","author":"Celio","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0140","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor\u2013positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0145","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0150","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ejca.2012.03.002","article-title":"Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer","volume":"48","author":"Bartsch","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejca.2007.11.007","article-title":"Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer","volume":"44","author":"Young","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"Ali","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0165","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor\u2013positive breast cancer","volume":"16","author":"Johnston","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0170","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2013.09.015_b0175","first-page":"243","article-title":"Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4\/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (BC)","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0180","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","article-title":"What is triple-negative breast cancer?","volume":"44","author":"Irvin","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clbc.2012.09.002","article-title":"Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome","volume":"13","author":"Montagna","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0200","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/annonc\/mdp492","article-title":"Triple-negative breast cancer \u2013 current status and future directions","volume":"20","author":"Gluz","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PPO.0b013e3181d24ff7","article-title":"Triple-negative breast cancer: role of specific chemotherapy agents","volume":"16","author":"Isakoff","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2013.09.015_b0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-010-0985-x","article-title":"Re-searching anthracycline therapy","volume":"123","author":"Oakman","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2013.09.015_b0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O\u2019Shaughnessy","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0230","article-title":"A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (G\/C) in metastatic triple-negative breast cancer (TNBC)","volume":"29","author":"O\u2019Shaughnessy","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0240","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0245","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2013.09.015_b0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.breast.2010.11.008","article-title":"Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research","volume":"20","author":"Goel","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2013.09.015_b0260","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2\u2013positive breast cancer: the HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0265","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.breast.2008.03.006","article-title":"Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? a mono-institutional experience and systematic review of observational studies","volume":"17","author":"Fabi","year":"2008","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2013.09.015_b0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.1062","article-title":"Observational demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab","volume":"26","author":"Menard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0280","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0285","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1634\/theoncologist.2009-0029","article-title":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational hermine study","volume":"15","author":"Extra","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.09.015_b0290","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03\u201305 study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0295","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0300","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG)","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0305","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","article-title":"Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer","volume":"24","author":"Gabos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0310","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0315","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0320","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","article-title":"Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases","volume":"105","author":"Lin","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl. 9","key":"10.1016\/j.ctrv.2013.09.015_b0330","doi-asserted-by":"crossref","first-page":"ixe5","DOI":"10.1016\/S0923-7534(20)34361-1","article-title":"CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) vs. trastuzumab plus capecitabine (TC)","volume":"23","author":"Pivot","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0335","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0340","article-title":"Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31\/GSK EGF 108919","volume":"30","author":"Gelmon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0345","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"24 Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0355","first-page":"64S","volume":"72","author":"Swain","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0360","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0365","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0370","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1158\/1078-0432.CCR-04-2569","article-title":"A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer","volume":"11","author":"De Laurentiis","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0375","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0380","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdg483","article-title":"Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?","volume":"14","author":"Jones","year":"2003","journal-title":"Ann Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0385","doi-asserted-by":"crossref","first-page":"889s","DOI":"10.1158\/1078-0432.889s.11.2","article-title":"Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations","volume":"11","author":"Johnston","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0390","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0395","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","article-title":"Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer","volume":"15","author":"Schwartzberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.09.015_b0400","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","article-title":"Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer \u2013 results of the eLEcTRA trial","volume":"21","author":"Huober","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2013.09.015_b0405","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2013.09.015_b0410","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/1871520610909030348","article-title":"Mechanisms of trastuzumab resistance in breast cancer","volume":"9","author":"Tolaney","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.ctrv.2013.09.015_b0415","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0420","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0425","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/jco.2009.27.15_suppl.1004","article-title":"Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I\/II study","volume":"27","author":"Swaby","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0430","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mds284","article-title":"Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy","volume":"24","author":"Awada","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0435","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","article-title":"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab","volume":"133","author":"Lin","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"24 Suppl.","key":"10.1016\/j.ctrv.2013.09.015_b0440","article-title":"A phase 2, randomized, open-label, study of neratinib (HKI-272) vs. lapatinib plus capecitabine for 2nd\/3rd-line treatment of HER2\u00fe locally advanced or metastatic breast cancer","volume":"71","author":"Martin","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0445","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/annonc\/mdp447","article-title":"Activity of fulvestrant in HER2-overexpressing advanced breast cancer","volume":"21","author":"Robertson","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0450","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clbc.2011.03.003","volume":"11","author":"Hamberg","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2013.09.015_b0455","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-009-0498-7","article-title":"Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 trial group","volume":"119","author":"Inoue","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0460","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0465","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0470","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0475","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0480","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10637-009-9310-0","article-title":"Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials","volume":"29","author":"Lee","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2013.09.015_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0727-0","article-title":"Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials","volume":"122","author":"Valachis","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-30-54","article-title":"Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials","volume":"30","author":"Cuppone","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0495","first-page":"CD008941","article-title":"Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer","volume":"7","author":"Wagner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2013.09.015_b0500","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr2642","article-title":"Antiangiogenic therapy for breast cancer","volume":"12","author":"Nielsen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0505","first-page":"3","article-title":"The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients","volume":"13","author":"Klijn","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ctrv.2013.09.015_b0510","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"24 Suppl. 2","key":"10.1016\/j.ctrv.2013.09.015_b0515","article-title":"Cetuximab+cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial","volume":"70","author":"Baselga","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0520","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jnci\/djp235","article-title":"International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy","volume":"101","author":"Cardoso","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0525","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0530","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2013.09.015_b0535","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-011-1875-6","article-title":"Beyond taxanes: the next generation of microtubule-targeting agents","volume":"133","author":"Cortes","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0540","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2008.19.5396","article-title":"Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy","volume":"27","author":"Le Scodan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0545","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-009-0670-0","article-title":"Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature","volume":"120","author":"Ruiterkamp","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0550","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-008-0101-7","article-title":"Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival","volume":"115","author":"Bafford","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0555","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrclinonc.2011.88","article-title":"Local treatment of metastatic cancer-killing the seed or disturbing the soil?","volume":"8","author":"Morgan","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0560","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1524-4741.2009.00744.x","article-title":"Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (Protocol MF07-01): a study of Turkish federation of the national societies for breast diseases","volume":"15","author":"Soran","year":"2009","journal-title":"Breast J"},{"key":"10.1016\/j.ctrv.2013.09.015_b0565","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-009-0655-z","article-title":"Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy","volume":"120","author":"Sparano","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2013.09.015_b0570","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0575","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1245\/s10434-010-1016-1","article-title":"Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?","volume":"17","author":"Pockaj","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0580","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejso.2011.04.013","article-title":"Liver resection and local ablation of breast cancer liver metastases \u2013 a systematic review","volume":"37","author":"Bergenfeldt","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0585","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijsu.2011.01.009","article-title":"Resection of liver metastases from breast cancer: towards a management guideline","volume":"9","author":"Howlader","year":"2011","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2013.09.015_b0590","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0595","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s11547-011-0634-4","article-title":"High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results","volume":"116","author":"Orgera","year":"2011","journal-title":"Radiol Med"},{"key":"10.1016\/j.ctrv.2013.09.015_b0600","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2007.03.056","article-title":"Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer","volume":"69","author":"Coldwell","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2013.09.015_b0605","doi-asserted-by":"crossref","first-page":"W66","DOI":"10.2214\/AJR.09.3836","article-title":"Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer","volume":"196","author":"Vogl","year":"2011","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0610","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1227\/NEU.0b013e31820773b2","article-title":"Trends in survival after surgery for breast cancer metastatic to the brain and spinal column in medicare patients: a population-based analysis","volume":"68","author":"Cahill","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ctrv.2013.09.015_b0615","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3171\/2010.8.JNS10461","article-title":"Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article","volume":"114","author":"Kondziolka","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2013.09.015_b0620","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrclinonc.2010.119","article-title":"Whole-brain radiation therapy in breast cancer patients with brain metastases","volume":"7","author":"Chargari","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0625","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-009-0062-7","article-title":"The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"Mehta","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0630","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.ijrobp.2011.02.019","article-title":"Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases","volume":"82","author":"Chao","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2013.09.015_b0635","first-page":"13","article-title":"Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: a prospective study using quality-of-life assessment","volume":"57","author":"Cheung","year":"2006","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.ctrv.2013.09.015_b0640","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0645","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CCO.0b013e328347918b","article-title":"New developments for treatment and prevention of bone metastases","volume":"23","author":"Body","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0650","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0655","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2835","article-title":"Therapeutic targets for bone metastases in breast cancer","volume":"13","author":"Clezardin","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2013.09.015_b0660","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2010-0278","article-title":"In the end what matters most? a review of clinical endpoints in advanced breast cancer","volume":"16","author":"Verma","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.09.015_b0665","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression to free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2013.09.015_b0670","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10147-011-0260-0","article-title":"Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer","volume":"17","author":"Hayashi","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0675","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1634\/theoncologist.2009-0145","article-title":"Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review","volume":"15","author":"Rosen","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2013.09.015_b0680","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2009.25.4011","article-title":"Emerging targeted therapies for breast cancer","volume":"28","author":"Alvarez","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.09.015_b0685","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4161\/cbt.11.9.15045","article-title":"Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications","volume":"11","author":"Garrett","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2013.09.015_b0690","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.breast.2011.02.006","article-title":"Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative","volume":"20","author":"El Saghir","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2013.09.015_b0695","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2146\/ajhp070629","article-title":"Projecting future drug expenditures-2008","volume":"65","author":"Hoffman","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ctrv.2013.09.015_b0700","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/11535560-000000000-00000","article-title":"Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review","volume":"28","author":"Blank","year":"2010","journal-title":"Pharmacoeconomics"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:01:19Z","timestamp":1688515279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213002041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0305737213002041"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.09.015","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time for more optimism in metastatic breast cancer?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}